MS treatment Flashcards

1
Q

relpase of ms ttt

A

methypredinsalone
IV ; 1gm /day ; 3 - 5 days
po ; 50 mg/d for 5 dyas

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

dmd aim

A
  1. reduce relapse frequency and severity
  2. prossive disaability to be avoided
    3.reduce disability from relapse
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

first line treatment of dmd

A

interferone or galitramer acteate

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

action of interferone

A

*Reduces leukocyte proliferation
*Reduces antigen presentation
*Modulates cytokine production
*Reduces T cell migration

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

names of drugs of interferone

A

Avonex Intramuscular β-interferon-1a 30ug once/week
› Rebif Subcutaneous β-interferon-1a 22 or 44ug 3 times/week
› Betaferon Subcutaneous β-beta interferon-1b 250ug alternate days

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

advantages of beta interferone

A

Modulates immune system
* Reduces relapse rate by 30%
* Reduces severe relapses by 50%
* Slows disability and cognitive impairment in relapsing remitting MS
by ~ 20%
* Reduces new MRI lesions by 50-70%
* No effect on primary orsecondary progression
* Long term effects (beyond 2-3 years) uncertain

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

side effect beta interferone

A

Flu-like symptoms, muscle aches, headache
* Injection site reactions (subcutaneous β- IFNs)
* Decreased white cell count, liver dysfunction
* Hair loss
* Depression
* Thyroid diseases

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

interferone must be followed up by

A

cbc and liverfunction because ; decrease wbcs and liver cell dysfunction

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

glatriamer acetate [ copaxone ]

A

Mechanism of action: Shift the population from TH1 cells to Th2 regulatory cells to suppress
the immune response.
* Cause in situ bystander suppression of auto-aggressive TH1 T cells

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

advantages of glatriamer

A

Regulates immune system
* Reduces relapse rate by 30%
* No effect on primary progressive MS
* No trials in secondary progressiveM

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

side effect of capoxane

A

injection site reaction
hypersenstivity [ rare]
allergic reactions ; chest tightness , shortness of breath , palpitations
loss of fat under site lipoatrophy at injection site

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

NHS “risk sharing scheme” guidelines for ß interferon & Galtiramer
actetate in RR M

A
  • Two relapses in Two year
  • Able to walk with or without assistance
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

NHS “risk sharing scheme” guidelines for ß interferon (1-b) in RR MS

A
  • Two relapses in two years
  • Able to walk at least 10 m with or without assistance
  • Minimal increase in disability due to slow progression over 2 years
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

natluzimab [ biiological ]

A

humanized antibody

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

natalizumab [tysabri]

A

given once per month

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

adavntages of natalizumab

A

reduce relapse rate by 68 percent
80-90 percent reduce new mri lesion
reduce rate of disability progression by 42 percent

17
Q

side effect of natalizumab

A

Infections
* Infusion (allergic) and hypersensitivity
reactions
* Urticaria
* Headache
* Dizziness
* Vomiting, nausea
* Arthralgia
* Progressive multifocal
leukoencephalopathy (PML) (1:500)a

18
Q

natalizumab) increases the risk of PML, an opportunistic viral infection of the brain that usually leads to death or severe disability. Risk factors for the development of PML include the presence of anti-JCV antibodies, duration of therapy, and prior use of immunosuppressants.

A

serious side effect

19
Q

indications fo use natalizumab

A

1.Natalizumab is recommended by NICE for rapidly
evolving severe RRMS (first line treatment)
* 2 or mores disabling attacks per year AND
* One or more enhancing lesions or significant
increase in T2 load compared with previous MRi
2.Natalizumab is also recommended by
NICE for RR MS with high disease activity
despite ß interferon (second line
treatment)
* 1 relapse in previous year while on
therapy AND
* At least 9 T2 lesions or one enhancing
lesion

20
Q

Teriflunomide (Aubagio)

A

Mechanism of action: Decrease in lymphocytic profileration.
* Effectiveness: Relapse reduction rate of approx. 30%
* Indication: RRMS

21
Q

side effect of aubigo

A

: slight thrombocyte and leukocyte reduction, gastrointestinal
symptoms, hepatic impairment, reversible hair thinning, peripheral neuropathies
and acute uric acid nephropathy

22
Q

Dimethyl fumarate (Tecfidera):

A

Mechanism of action: amplification of Th2 responses
Has antioxidative and immunoregulatory effects
Modulation of the differentiation of antigen presenting cells.
* Effectiveness: reduction of relapse rate by approx. 50% vs. placebo
* Indication: RRMS

23
Q

side effects of tecfidera

A

GIT upset
lymphopenia
pml

24
Q
  • Fingolimod (Gilenya
A

Was the first oral FDA approved drug for relapsing form of MS

25
Q

Fingolimod (Gilenya):

A
  • Mechanism : Binds to SP1 receptor on lymphocyte , the receptor becomes
    internalized and it causes the lymphocyte to be sequestrated in lymphoid tissue.
  • Effectiveness: reduction in the rate of relapses by approx. 55% vs. placebo
  • Indication: RRMS (either insufficient response to existing immunomodulatory
    therapy or non-pretreated high-risk patients, i.e., at least two relapses with
    disability progression in the last year, and detection of new disease activity by MRI)
  • Main side effects: VZV reactivation, PML cases, basal cell carcinoma, transient
    bradycardia, macular edema, haemophagocytic syndrome
26
Q

indications of gilenya

A

RRMS (either insufficient response to existing immunomodulatory
therapy or non-pretreated high-risk patients, i.e., at least two relapses with
disability progression in the last year, and detection of new disease activity by MRI)

27
Q

Ocrelizumab (Ocrevus)

A

Effectiveness: Reduction in relapse rate of approx. 46-47% vs. IFN, reduction
in disability progression by 24%
*
indications ; RRMS and PPMS

28
Q

Alemtuzumab

A

s a humanized monoclonal antibody directed against CD52
which depletes lymphocytes.

29
Q

ALEMTUZUMAB

A

Indication: RRMS with at least two relapses over the past two years during at
least six months of immunomodulatory therapy or particularly active
untreated patients if they have suffered a very high rate of relapse

30
Q

summary of the treatment dmd

A

First-line injectables such as beta-interferon and glatiramer
New oral agents such as dimethyl fumarate, teriflunomide and fingolimod
Biologics such as natalizumab and alemtuzumab.